Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

PHASE2TerminatedINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

MBX-102

capsule

DRUG

Placebo

matching placebo

DRUG

Actos

over-encapsulated to match MBX-102 and placebo

DRUG

Metformin

greater than or equal to 1500 mg/kg day

Trial Locations (26)

27103

Piedmont Medical Research Associates, Winston-Salem

50008

Kamineni Hospitals Pvt, Ltd., Hyderabad

78229

DGD Research, Inc., San Antonio

89101

Nevada Alliance Against Diabetes, Las Vegas

90017

American Institute of Research, Los Angeles

91505

Providence Clinical Research, Burbank

400067

Diabetes Action Centre, Mumbai

Unknown

Bangalore Diabetes Centre, Bangalore

Diacon Hospital Diabetes & Research Centre, Bangalore

M. S. Ramaiah Memorial Hospital, Bangalore

St. John's Medical College & Hospital, Bangalore

Dr. V. Seshiah Diabetes Care & Research Institute, Chennai

Mediciti Hospital, Hyderabad

Medwin Hospital, Hyderabad

Diabetes Thyroid Hormone Research Institute Pvt. Ltd., Indore

Fortis Hospital, Jaipur

Bharti Research Institute of Diabetes & Endocrinology, Karnāl

Amrita Institute of Medical Sciences, Kochi

BYL Nair Hospital, Mumbai

PD Hindhuja National Hospital, Mumbai

Gandhi Endocrinology & Diabetes Centre, Nagpur

All India Institute of Medical Sciences, New Delhi

Deenanath Mangeshkar Hospital & Research Centre, Pune

Diabetes Care & Research Centre, Pune

Health & Research Centre, Trivendrum

Christian Medical College, Vellore

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT00814372 - Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin | Biotech Hunter | Biotech Hunter